Related by context. All words. (Click for frequent words.) 82 complete cytogenetic 78 cytogenetic responses 77 CCyR 77 MCyR 75 remission CR 73 complete cytogenetic response 73 CR CRu 73 partial remissions 72 complete remissions 71 response CCyR 70 patients evaluable 70 evaluable patients 70 chlorambucil 70 HBeAg positive patients 69 splenectomized patients 69 CRp 69 tumor shrinkage 69 hematologic toxicity 69 CR nPR 69 Solid Tumors criteria 69 pCR 68 virologic response 68 TEAEs 68 annualized relapse 68 ACR# response 68 nodular partial response 68 sustained virologic response 68 evaluable subjects 68 Response Evaluation Criteria 67 RECIST Response Evaluation Criteria 67 receiving golimumab 67 RECIST criteria 67 postoperative chemotherapy 67 sustained virological response 67 certolizumab 67 Events MACE 67 tumor regressions 67 lymphopenia 67 ACR Pedi 67 heavily pretreated 66 response pCR 66 Ph + 66 achieved ACR# 66 DAS# remission 66 evaluable 66 virologic failure 66 REYATAZ r arm 66 ALT flares 66 plus methotrexate 66 elevated ALT 66 EDSS scores 66 MACCE 66 lymphocytosis 66 mg kg dose 66 undetectable HBV DNA 66 CIMZIA TM 66 HBeAg seroconversion 66 events MACE 66 tumor regression 66 Ph + ALL 66 definite stent thrombosis 66 Rate ORR 66 confirmed CCyR 66 imatinib therapy 66 severe exacerbations 66 metastatic GIST 66 biochemical relapse 66 Scale EDSS 65 plus dexamethasone 65 prior chemotherapy regimens 65 DLTs 65 nilotinib 65 clinically meaningful improvement 65 FOLFOX4 65 SVR# 65 graft dysfunction 65 PASI scores 65 PREZISTA r arm 65 Flu Cy 65 morphometric vertebral fractures 65 secondary efficacy endpoint 65 cytoreduction 65 laboratory abnormalities 65 virological response 65 placebo dexamethasone 65 refractory NSCLC 65 peripheral sensory neuropathy 65 mg BID 65 haematologic 65 docetaxel chemotherapy 65 progression TTP 65 HSCT 65 dosing cohorts 65 hematologic 65 nadolol 65 ACTEMRA TM 64 Free Survival PFS 64 dasatinib 64 ACR# responses 64 achieved PASI 64 gout flares 64 prior relapsers 64 8mg/kg 64 lopinavir r arm 64 PSA nadir 64 FluCAM 64 recurrent VTE 64 achieved CCyR 64 metastatic CRC 64 CIMZIA ™ 64 locoregional recurrence 64 heavily pretreated patients 64 imatinib 64 dose limiting toxicities 64 follicular lymphomas 64 histologic subtype 64 radiographic progression 64 sUA 64 mcg BID 64 mRCC 64 neoadjuvant chemotherapy 64 FluCAM arm 64 Primary endpoints 64 endoscopic remission 64 Partial Responses 64 dexamethasone Decadron 64 HBeAg negative patients 64 adalimumab 64 neoadjuvant 64 mg BID dose 64 Index CDAI 64 relapsed MM 63 microbiological eradication 63 4mg/kg 63 chemoradiation 63 clodronate 63 Solid Tumors RECIST 63 cEVR 63 XIENCE V PROMUS Stent 63 cystectomy 63 Expanded Disability Status 63 platinum refractory 63 FOLPI 63 HBeAg 63 discontinuations due 63 achieved sustained virologic 63 leukemia AML 63 adjunctive placebo 63 Median progression 63 CIMZIA TM certolizumab pegol 63 tumor necrosis 63 mucosal healing 63 Follicular Lymphoma 63 liver histology 63 SUVmax 63 ALND 63 aspartate aminotransferase AST 63 follicular NHL 63 Secondary endpoints include 63 Scale EDSS score 63 underwent resection 63 virological failure 63 secondary efficacy endpoints 63 bortezomib refractory 63 ribavirin therapy 63 ipsilateral stroke 63 serum clusterin levels 63 chemoradiotherapy 63 octreotide LAR 63 secondary endpoint 63 DMARD 63 limiting toxicity 63 Solid Tumors 63 alanine aminotransferase ALT 63 dose cohort 63 tumor recurrence 63 Psoriasis Area 63 myelosuppression 63 serologically active patients 63 mg ustekinumab 63 achieved sustained virological 63 Secondary endpoints 63 BARACLUDE ® 63 serum HBV DNA 63 biochemical recurrence 63 blastic phase 63 receiving INTRON 63 HER2 overexpression 63 EGFR TKI 63 recurrent glioblastoma multiforme 62 leukemia ALL 62 mcg QD 62 Partial Response 62 oxycodone CR 62 adjunctive ABILIFY 62 CIN3 62 somatostatin analog 62 #mg BID [001] 62 PROMACTA 62 desvenlafaxine succinate 62 plasma uric acid 62 acute GvHD 62 #mg/m# [001] 62 Doxil ® 62 Crohn Disease Activity 62 locoregional 62 mycophenolate mofetil 62 dasatinib Sprycel ® 62 EDSS score 62 ACR# ACR# 62 metastatic malignant 62 HDRS 62 EXJADE 62 OAB symptoms 62 log# copies mL 62 SCr 62 histologically confirmed 62 lymphoid blast 62 FOLFIRI 62 neutrophil count 62 stage IIIB 62 imipenem 62 carboplatin paclitaxel 62 tolvaptan 62 oblimersen 62 paclitaxel cisplatin 62 log# reduction 62 severe neutropenia 62 log# IU mL 62 relapsed AML 62 DOXIL 62 debulking surgery 62 standard chemotherapy regimen 62 Complete Response CR 62 mg QD 62 irbesartan 62 events AEs 62 galiximab 62 rosuvastatin #mg 62 refractory AML 62 oral allopurinol 62 #mg QD [002] 62 CANCIDAS 62 RECIST 62 undetectable HCV RNA 62 rapid virologic response 62 aminotransferase elevations greater 62 LEXIVA r 62 febrile neutropenia 62 Fludara 62 estimated glomerular filtration 62 trastuzumab Herceptin ® 62 HER2 expression 62 pegylated interferon alpha 62 alfa 2a 62 BENICAR HCT 62 Secondary endpoints included 62 remission induction 62 ribavirin RBV 62 glycated hemoglobin levels 62 elotuzumab 62 receiving VICTRELIS 62 stage IIIb IV 62 comparator arm 62 MADRS score 62 mg/m2 dose 61 invasive aspergillosis 61 operable breast cancer 61 decitabine 61 Infusion Reactions Severe 61 neoadjuvant radiation 61 tumor resection 61 baseline HbA1c 61 TNF antagonist 61 thromboembolic events 61 thrombocytopenic 61 T#I mutation 61 HAM D# scores 61 PSADT 61 distant metastasis 61 nonresponders 61 mcg albinterferon alfa 2b 61 Kaplan Meier analysis 61 median PFS 61 cytopenias 61 prospectively defined 61 dosing cohort 61 cisplatin gemcitabine 61 Neoadjuvant 61 ara C 61 relapsed MCL 61 neutropenia dehydration dyspnea 61 cytologically confirmed 61 elevated transaminases 61 essential thrombocythemia 61 daunorubicin 61 APTIVUS r 61 mcg kg REBETOL 61 preoperative chemotherapy 61 free survival PFS 61 neutropaenia 61 recurrent GBM 61 recurrent venous thromboembolism 61 HCV RESPOND 2 61 peg interferon 61 Raptiva r 61 receiving highly emetogenic 61 virologic suppression 61 binary restenosis 61 dose cohorts 61 rFVIIa 61 PegIFN RBV 61 virologic responses 61 R0 resection 61 permanently discontinue Vectibix 61 nab paclitaxel 61 metastatic RCC 61 histological subtype 61 cytogenic 61 events SAEs 61 generalized edema 61 recurrent malignant glioma 61 platelet reactivity 61 -#.# log# 61 graft occlusion 61 aspartate aminotransferase 61 hypoglycemic events 61 serum phosphate 61 dose escalation phase 61 leukemia APL 61 tamoxifen therapy 61 NYHA functional class 61 composite endpoint 61 metastatic malignant melanoma 61 renal flares 61 Renal Cell Carcinoma RCC 61 #mg dose [002] 61 nucleoside naive 61 intravascular hemolysis 61 subtrochanteric 61 neoadjuvant therapy 61 dalteparin 61 CsA 61 biliary tract cancer 61 VGPR 61 histologies 61 plus MTX 61 Thrombocytopenia 61 papillary renal cell carcinoma 61 SUTENT 61 DAS# CRP 61 azacytidine 61 VELCADE melphalan 61 postoperative mortality 61 dacarbazine 61 corticosteroid dose 61 Castration Resistant Prostate Cancer 61 % CI #.#-#.# [003] 61 Sustained Virological Response 61 q#d 61 dasatinib Sprycel 61 serum HCV RNA 61 vincristine doxorubicin 61 distant metastases 61 mcg Albuferon 61 FOLFOX 61 peginterferon 61 adriamycin 61 low dose cytarabine 61 CHOP chemotherapy 61 intravesical 61 chronic myeloid leukemia CML 61 tapentadol ER 61 alanine aminotransferase 61 IFN α 61 nonfatal MI 61 plus ribavirin 60 cervical intraepithelial neoplasia 60 perioperative complications 60 reinfarction 60 median survivals 60 tumor lysis syndrome 60 alicaforsen enema 60 posaconazole 60 Kaplan Meier estimates 60 #mg BID [003] 60 estramustine 60 plus prednisone 60 biventricular repair 60 mCi kg 60 PEGINTRON TM 60 severe oral mucositis 60 NATRECOR R 60 seroprotection 60 chemoradiation therapy 60 radical prostatectomy RP 60 metastatic renal cell carcinoma 60 tirofiban 60 CLL SLL 60 neurologic progression 60 cabazitaxel 60 Hycamtin ® 60 amoxicillin clavulanate 60 azacitidine 60 CDAI 60 R# #mg BID 60 â ‰ ¥ 60 fosamprenavir 60 doxorubicin cyclophosphamide 60 LHRH analogues 60 leucopenia 60 Dasatinib 60 RGT arm 60 HBV DNA levels 60 hematological toxicity 60 PRADAXA #mg 60 adefovir treated 60 curative resection 60 INCB# [003] 60 NMIBC 60 FOLFIRINOX 60 perioperative mortality 60 inflammatory lesions 60 hypophosphatemia 60 goserelin 60 cytoreductive surgery 60 INC# 60 cell lymphoma CTCL 60 androgen suppression 60 Sustained virologic response 60 tipranavir r 60 pegylated interferon alfa 60 TORISEL 60 androgen deprivation 60 CRu 60 corticosteroid therapy 60 gemcitabine Gemzar 60 recurrent NSCLC 60 topotecan 60 prednisone prednisolone 60 calculated creatinine clearance 60 TAXUS p value 60 visceral metastases 60 TMC# r 60 intracranial hemorrhage ICH 60 FOLFOX6 60 ertapenem 60 gemcitabine carboplatin 60 seropositive patients 60 Fludarabine 60 macroalbuminuria 60 timepoint 60 lumbar spine BMD 60 Hypotension 60 postoperative complication 60 moderate renal impairment 60 bevacizumab Avastin ® 60 angiographic restenosis 60 leukemia CML 60 endometrial carcinoma 60 rebleeding 60 rFSH 60 ritonavir boosted 60 methotrexate monotherapy 60 NLX P# 60 EBMT criteria 60 genotypic resistance 60 relapsed CLL 60 Virologic 60 fibrinolysis 60 fluvastatin 60 HER2 positive metastatic breast 60 K ras mutations 60 ALT elevation 60 melphalan prednisone 60 HUMIRA achieved PASI 60 atrioventricular block 60 Operative mortality 60 % Confidence Interval 60 peginterferon alfa 2a 60 IV NSCLC 60 cerebrovascular events 60 spontaneous bowel movements 60 detectable HCV RNA 60 CMV disease 60 XIENCE V demonstrated 60 seroconversion 60 liver metastases 60 pT3 60 viral kinetics 60 nephrotoxicity 60 Decitabine 60 RRMS patients 60 Median PFS 60 efficacy endpoint 60 posttransplant 60 adjuvant hormonal therapy 60 ULORIC 60 HBeAg positive 60 Folfox 60 Cutaneous T 60 μg dose 60 PEG IFN 60 epithelial tumors 60 virologic breakthrough 60 QTc prolongation 60 SCIg 60 huN# DM1 60 lymphadenectomy 60 posttreatment 60 relapsed refractory 60 radioiodine therapy 60 SLNB 60 APTIVUS R 60 Irinotecan 60 eosinophilic asthma 59 Amrubicin 59 chronic GVHD 59 fallopian tube cancers 59 pT2 59 orchiectomy 59 teriflunomide 59 antibody titer 59 receptor tyrosine kinase inhibitor 59 octreotide 59 MAGE A3 ASCI 59 hepatitis C genotype 59 rituximab refractory 59 CIN2 + 59 bendamustine 59 DAPT 59 serum testosterone 59 radiochemotherapy 59 hepatorenal syndrome 59 Pegasys ® 59 hypomagnesemia 59 breast carcinomas 59 flutamide 59 serum prostate 59 conjunctival hyperemia 59 anthracycline taxane 59 abnormal p# biomarker 59 squamous histology 59 ALT elevations 59 sunitinib 59 tenecteplase 59 pyrexia mucositis sepsis febrile 59 riociguat 59 symptomatic VTE 59 imatinib resistant 59 idarubicin 59 Hematologic toxicity 59 PEGylated anti 59 ARB telmisartan 59 hepatic metastases 59 lenalidomide Revlimid R 59 piperacillin tazobactam 59 iPTH 59 transaminase elevations 59 liver resection 59 hyperphenylalaninemia HPA due 59 previously untreated follicular 59 aplastic anemia AA 59 asymptomatic carotid stenosis 59 interferon alfa 2b 59 biologic therapy 59 prostate cancer CaP 59 endothelin receptor antagonists 59 prospectively stratified 59 serum cortisol 59 myelodysplastic myeloproliferative diseases 59 abacavir lamivudine 59 PREZISTA r 59 Tumor shrinkage 59 lymph node dissection 59 ug dose 59 IIIa inhibitor 59 Pegylated Liposomal Doxorubicin 59 abdominal pain abdominal discomfort 59 Natalizumab 59 EURIDIS 59 interferon beta therapy 59 systemic ALCL 59 plus prednisone prednisolone 59 underwent surgical resection 59 KRAS mutations occur 59 mcg kg 59 infliximab 59 oral rivaroxaban 59 #mg/day [002] 59 p = NS 59 prednisone prednisolone plus 59 HbA 1c levels 59 locoregional disease 59 mg qd 59 adverse cytogenetics 59 carotid stenosis 59 Xanafide 59 parathyroidectomy 59 virologic response EVR 59 Newly Diagnosed Multiple Myeloma 59 FIRMAGON 59 Bezielle 59 neoadjuvant treatment 59 temsirolimus 59 GnRH agonist 59 alkylating agent 59 steroid dexamethasone 59 histologically proven 59 leukopenia 59 anemia hemoglobin 59 clinically meaningful improvements 59 moderately emetogenic 59 pediatric acute lymphoblastic 59 BENICAR 59 mg kg cohorts 59 familial amyloidotic polyneuropathy FAP 59 IELT 59 TACE 59 5-FU/LV 59 adjuvant radiotherapy 59 pegylated liposomal doxorubicin 59 pancreatic adenocarcinoma 59 systemic embolism 59 reintervention 59 pramipexole 59 metastatic renal cell 59 non splenectomized 59 VUR 59 % CI #.#-#.# [007] 59 pneumonectomy 59 NRTI 59 serum urate 59 adenoma recurrence 59 Median survival 59 mitoxantrone 59 Thrombolysis 59 imatinib Gleevec 59 generalized seizures 59 aminotransferase ALT 59 5-fluorouracil/leucovorin 59 quetiapine XR 59 dose melphalan 59 FOLPI regimen 59 liver enzymes ALT 59 relapsers 59 CYT# potent vascular disrupting 59 gastrointestinal stromal tumors GIST 59 BEXXAR Therapeutic Regimen 59 demonstrated antitumor activity 59 mesalamine granules 59 Trastuzumab 59 IRLS score 59 advanced adenoma 59 iniparib BSI 59 mCRC patients 59 postintervention 59 del 5q MDS 59 Gleevec resistant 59 A1c levels 59 myelofibrosis polycythemia vera 59 undetectable viral load 59 HBV DNA 59 hypercalcemia 59 DAS# [002] 59 arterial thromboembolic events 59 Postoperative complications 59 inhospital 59 Nilotinib 59 follicular lymphoma 59 dosage regimens 59 refractory CTCL 59 LHRH antagonists 59 interferon ribavirin 59 ABSORB trial 59 Telintra 59 docetaxel Taxotere ® 59 invasive candidiasis 59 dacarbazine DTIC 59 CYPHER Stent 59 viral suppression 59 HGPIN 59 bosentan 59 tumor histology 59 briakinumab 59 cisplatin chemotherapy 59 mitoxantrone chemotherapy 59 ASCT 59 erlotinib Tarceva ® 59 trials RCTs 59 lung metastases 59 hepatic cirrhosis 59 ACR# [002] 59 eplerenone 59 recanalization 58 HBsAg 58 metastatic lesions 58 chloride secretion 58 gastrointestinal stromal tumor GIST 58 tipranavir 58 achieving PASI 58 AGILECT R 58 Hb A1C 58 NAbs 58 myeloid blast 58 protease inhibitor PI 58 cerebral vasospasm 58 Toxicities 58 β blockers 58 acneform rash 58 oral diclofenac 58 unfractionated heparin UFH 58 pelvic lymphadenectomy 58 crizotinib PF # 58 colectomy 58 placebo controlled clinical 58 atherogenic dyslipidemia 58 p = #.# [003] 58 lamivudine monotherapy 58 radical nephrectomy 58 HCV RNA 58 venlafaxine XR 58 cyclophosphamide methotrexate 58 Virologic failure 58 atazanavir ritonavir 58 hematologic adverse 58 sensory neuropathy 58 Ozarelix 58 vandetanib 58 TO AVOID PREGNANCY WHILE 58 lopinavir r 58 refractory metastatic 58 Taxotere ® 58 Zometa hazard 58 Severity Index PASI 58 QTcF 58 nodal metastases 58 haematological 58 baseline LDH 58 nucleoside naive patients 58 EDARBI 58 unresectable 58 completely resected 58 Pharmacokinetics PK 58 Elitek 58 refractory cutaneous T 58 Soft Tissue Sarcoma 58 icatibant 58 myeloproliferative diseases 58 carboplatin 58 TIMP 1 58 hepatectomy 58 repeat paracentesis 58 MoxDuo TM IR 58 COPAXONE R 58 dose dexamethasone 58 concomitant antibiotics 58 cardiovascular calcification 58 alteplase 58 anagrelide 58 adenotonsillectomy 58 esophageal candidiasis 58 Kaplan Meier estimate 58 tipranavir ritonavir 58 cells mcL 58 achieve sustained virologic 58 adefovir 58 Q#IR 58 PAOD 58 relapsed refractory multiple myeloma 58 Retreatment 58 Chronic Lymphocytic Leukemia CLL 58 microgram kg 58 bFGF 58 blood phenylalanine Phe 58 CD4 + cell 58 mg/m2/day 58 virologic 58 prespecified secondary 58 urinary N telopeptide 58 pertuzumab 58 placebo p = 58 indolent NHL 58 pancreatic resection 58 allogeneic SCT 58 weekly CSBMs 58 mcg linaclotide 58 dose cytarabine 58 recurrent genital herpes 58 Lupuzor ™ 58 decompensated liver disease 58 proteinuria 58 bolus dose 58 XELOX 58 antibody titers 58 Betaferon ® 58 hypogonadal men 58 death reinfarction 58 Zevalin R Ibritumomab 58 relapsing multiple sclerosis 58 MabCampath 58 paraprotein 58 beta blocker therapy 58 #.#ng/ml 58 doxorubicin docetaxel 58 HES CEL 58 #mg/day [001] 58 NNRTI resistance 58 superficial bladder cancer 58 vWD 58 folinic acid 58 etanercept 58 Solid Tumours 58 plasma HCV RNA 58 chemo radiotherapy 58 Hepatocellular Carcinoma HCC 58 T#I [002] 58 refractory gout 58 chronic eosinophilic leukemia 58 ximelagatran 58 intravitreal injections 58 liver transplant recipients 58 postdose 58 Hazard Ratio 58 sarcomatoid 58 non hematological toxicities 58 external beam radiotherapy 58 dose titration 58 CAMMS# 58 HCV SPRINT 58 metastatic neuroendocrine tumors 58 Montgomery Asberg Depression 58 treatment naive genotype 58 systemic corticosteroid 58 nausea photophobia 58 Durezol 58 HBeAg negative 58 external genital lesions 58 salmeterol fluticasone 58 splenectomized 58 intratumoral 58 RoACTEMRA 58 polyposis 58 pulmonary toxicity 58 refractory chronic lymphocytic 58 receiving Vectibix monotherapy 58 Secondary efficacy endpoints 58 telaprevir dosed 58 plus gemcitabine 58 aminotransferases 58 serum aminotransferase levels 58 DAS# scores 58 Diffuse Large B 58 nadroparin 58 intermittent dosing 58 rituximab 58 CLARITY study 58 hyperoxaluria 58 Elagolix 58 deep venous thromboses 58 peginterferon alfa 2b 58 renal cell carcinomas 58 anterior uveitis 58 histologic 58 tumor progression TTP 58 pegylated interferon alfa 2b 58 hemoglobin A1c levels 58 myocardial reperfusion 58 ponatinib 58 colorectal carcinoma 58 RSD# oral 58 pimecrolimus cream 58 vertebral fracture 58 Myelofibrosis 58 infliximab therapy 58 pyrazinamide 58 ATACAND 58 anemia neutropenia 58 cisplatin vinorelbine 58 MGd 58 nonvertebral fractures 58 discontinuations 58 gefitinib 58 sorafenib Nexavar 58 RLS symptoms 58 delayed onset CINV 58 recovery CRp 58 Peg IFN 58 nicardipine 58 primary generalized tonic 58 Rituximab 58 oral vancomycin 58 caspofungin 58 ACTEMRA 58 receiving prophylactic anticoagulation 58 RLAI 58 ibandronate 58 cinacalcet 58 pulmonary exacerbations 58 mg m² 58 tocilizumab 58 Oral Fingolimod 58 delayed CINV 58 alemtuzumab treated 58 histologically 58 neutrophil counts 58 Autologous Stem Cell Transplantation 58 mg TID 58 renal tumors 58 generalized tonic clonic seizures 58 HbA 1c 58 GLIADEL R Wafer 58 q#h 58 Aptivus ® 58 JAK2 V#F 58 5FU 58 Adenomas 58 autoantibody positive 58 entecavir 58 pegylated interferon alfa 2a 58 cutaneous melanoma 58 durable remissions 58 LymphoStat B belimumab 58 atypical ductal hyperplasia 58 highly emetogenic 58 DMARD therapy 58 PSMA ADC 58 #q# deletion syndrome 58 SPRYCEL ® 58 intravenous bisphosphonates 58 serum urate levels 58 incidence ≥ 58 weekly subcutaneous injections 57 sitaxsentan 57 log# 57 specific antigen PSA 57 PegIFN 57 myeloproliferative neoplasms 57 HIV HCV coinfected 57 XIENCE V vs. 57 Traficet EN 57 adrenalectomy 57 statistically significant efficacy 57 relapsed SCLC 57 fondaparinux 57 F FDG PET 57 triiodothyronine 57 bolus injection 57 CDAI score 57 PRADAXA 57 boosted protease inhibitor 57 myeloid 57 oral FTY# 57 hyperalgesia 57 Tumor Response 57 Subgroup analysis 57 neostigmine 57 LVEF 57 achieved statistical significance 57 EBRT 57 adalimumab Humira 57 thrombocytosis 57 serum phosphate levels 57 COPERNICUS 57 ACZ# 57 preoperative PSA 57 XEPLION R 57 relapsing remitting 57 transaminases 57 Kit CD# positive 57 sunitinib Sutent 57 intraocular inflammation 57 Omacetaxine 57 nonmetastatic prostate cancer 57 MALT lymphoma 57 lumiliximab 57 YERVOY 57 mitoxantrone plus 57 univariate analysis 57 HPV-#/# 57 Stage IIB 57 Myocardial Infarction Study 57 atherothrombotic disease 57 Bevacizumab 57 TroVax ® 57 DMARDs 57 thymoma 57 iniparib 57 pegylated alpha interferon 57 systemic corticosteroids 57 peginterferon alfa 2a #KD 57 timepoints 57 idiopathic thrombocytopenic purpura ITP 57 GnRH agonists 57 chronic myelogenous leukemia CML 57 cardiovascular hospitalizations 57 Imatinib 57 situ CIS 57 coronary revascularization